| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d137f8e7503ba75f6edf7cbdf54e98c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b1c054af6a01bf8a6508b1bc8f65c153 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-75
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-565
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2878 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2014-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5d66eae1618860d17d43f6c4391a88c0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6b4a055b48a7deb00d2a7b6323452d40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3ef16b40046b9f016b9ef6b0ed582ec5
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c796d186b55b281045ebe8b8db3f2e02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9e5257ee0e4be36def5c138ffc3aa05a |
| publicationDate |
2016-01-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20160006168-A |
| titleOfInvention |
Humanized anti-cd134(ox40) antibodies and uses thereof |
| abstract |
The present invention provides antibodies that specifically bind human CD134. Anti-human CD134 antibodies can be generated, for example, from non-OX40 ligand (s) of human CD134 expressed in activated human conventional effector CD4 and / or CD8 T lymphocytes (Teffs) and activated human inhibitory regulatory CD4 T lymphocytes ≪ / RTI > OX40L) binding domain of human CD134. Humanized anti-human CD134 antibodies are useful in the treatment of cancer (e. G., To confer Teffs anti-cancer effector function and / or inhibit Tregs inhibitory function). |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190013561-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190080760-A |
| priorityDate |
2013-03-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |